Fox Run Management L.L.C. Purchases New Position in Emergent Biosolutions Inc. $EBS

Key Points

• Fox Run Management L.L.C. has acquired 28,020 shares of Emergent Biosolutions Inc., valued at approximately $136,000, during the 1st quarter.
• Institutional investors own 78.40% of Emergent Biosolutions, with several firms increasing their stakes significantly, including a 198.9% increase by Prescott Group Capital Management.
• Emergent Biosolutions reported $0.16 earnings per share (EPS) for the last quarter, exceeding analysts' expectations of a loss, but noted a revenue shortfall compared to forecasts.

Fox Run Management L.L.C. acquired a new position in Emergent Biosolutions Inc. (NYSE:EBS - Free Report) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 28,020 shares of the biopharmaceutical company's stock, valued at approximately $136,000. Fox Run Management L.L.C. owned approximately 0.05% of Emergent Biosolutions as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently bought and sold shares of the business. Millennium Management LLC boosted its position in Emergent Biosolutions by 83.0% in the fourth quarter. Millennium Management LLC now owns 1,481,906 shares of the biopharmaceutical company's stock worth $14,167,000 after purchasing an additional 671,947 shares during the last quarter. Palisade Capital Management LP boosted its position in Emergent Biosolutions by 21.6% in the first quarter. Palisade Capital Management LP now owns 1,141,589 shares of the biopharmaceutical company's stock worth $5,548,000 after purchasing an additional 202,857 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in Emergent Biosolutions by 67.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,104,058 shares of the biopharmaceutical company's stock worth $10,554,000 after purchasing an additional 444,790 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its position in Emergent Biosolutions by 3.2% in the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 931,627 shares of the biopharmaceutical company's stock worth $4,528,000 after purchasing an additional 29,295 shares during the last quarter. Finally, Two Sigma Investments LP boosted its position in Emergent Biosolutions by 13.9% in the fourth quarter. Two Sigma Investments LP now owns 846,766 shares of the biopharmaceutical company's stock worth $8,095,000 after purchasing an additional 103,574 shares during the last quarter. 78.40% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen downgraded Emergent Biosolutions from a "buy" rating to a "hold" rating in a research note on Saturday, August 9th. Three research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $14.33.

Insider Buying and Selling at Emergent Biosolutions

In other Emergent Biosolutions news, Director Kathryn C. Zoon sold 7,086 shares of the stock in a transaction on Friday, August 15th. The stock was sold at an average price of $8.87, for a total value of $62,852.82. Following the sale, the director owned 71,799 shares in the company, valued at $636,857.13. This trade represents a 8.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Donald W. Degolyer sold 7,844 shares of the firm's stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $8.65, for a total value of $67,850.60. Following the transaction, the director owned 137,659 shares in the company, valued at approximately $1,190,750.35. This represents a 5.39% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 1.20% of the company's stock.

Emergent Biosolutions Price Performance

EBS stock traded down $0.0850 during midday trading on Friday, hitting $9.2350. The company's stock had a trading volume of 1,236,019 shares, compared to its average volume of 1,481,953. Emergent Biosolutions Inc. has a 12 month low of $4.02 and a 12 month high of $12.73. The company has a quick ratio of 3.00, a current ratio of 5.66 and a debt-to-equity ratio of 1.25. The firm has a market capitalization of $492.70 million, a price-to-earnings ratio of 3.77 and a beta of 1.97. The company has a 50 day moving average of $7.22 and a two-hundred day moving average of $6.48.

Emergent Biosolutions (NYSE:EBS - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported $0.16 earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.42. The business had revenue of $140.90 million during the quarter, compared to the consensus estimate of $148.55 million. Emergent Biosolutions had a return on equity of 24.63% and a net margin of 16.38%. On average, analysts expect that Emergent Biosolutions Inc. will post -0.63 EPS for the current year.

About Emergent Biosolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.